ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib is clinically used for the treatment of BCR-ABL+ leukemias, especially chronic myeloid leukemia (CML), because it blocks the deregulated tyrosine kinase ABL.